Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.57 |
| ▸ | BCHE | P06276 | 10/20 | 0.56 |
| ▸ | BACE1 | P56817 | 9/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384396 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL19223406 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL22623856 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL12385776 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL10236431 | 0.90 | ACHE (0.66) | ACHEBCHEBACE1CCR3HRH1 | |
| SCHEMBL2485710 | 0.87 | HRH1 (0.55) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL607896 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL3272029 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL607895 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL12384414 | 0.86 | FUCA1 (0.55) | ACHEBCHEBACE1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | ACHE 3072/4885BCHE 4849/4885BACE1 4505/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | ACHE 4786/4885BCHE 4788/4885BACE1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.